Innate Pharma 過去の業績
過去 基準チェック /06
Innate Pharmaの収益は年間平均-18.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間13.3% 23%割合で 減少しています。
主要情報
-18.60%
収益成長率
-17.00%
EPS成長率
| Biotechs 業界の成長 | 30.80% |
| 収益成長率 | -22.98% |
| 株主資本利益率 | n/a |
| ネット・マージン | -546.11% |
| 次回の業績アップデート | 17 Sep 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.ナラティブの更新 • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.ナラティブの更新 • Apr 09
IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.分析記事 • Mar 29
Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...
ナラティブの更新 • Mar 25
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.ナラティブの更新 • Mar 11
IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.ナラティブの更新 • Feb 25
IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.ナラティブの更新 • Feb 11
IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.ナラティブの更新 • Jan 27
IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).ナラティブの更新 • Jan 12
IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.分析記事 • Nov 17
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...ナラティブの更新 • Sep 18
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.分析記事 • Jul 19
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Innate Pharma S.A. ( EPA:IPH ) is a stock to avoid...
新しいナラティブ • Apr 04
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.分析記事 • Apr 02
News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Celebrations may be in order for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...分析記事 • Feb 22
Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Innate Pharma S.A. ( EPA:IPH ) shares have continued their recent momentum with a 26% gain in the last month alone. The...分析記事 • Dec 20
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Innate Pharma S.A. ( EPA:IPH ) shares have had a really impressive month, gaining 37% after a shaky period beforehand...分析記事 • Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
It's not a stretch to say that Innate Pharma S.A.'s ( EPA:IPH ) price-to-sales (or "P/S") ratio of 4.1x right now seems...分析記事 • May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 3.4x Innate Pharma S.A. ( EPA:IPH ) is definitely a stock...分析記事 • Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Innate Pharma S.A. ( EPA:IPH ) just released its latest annual results and things are looking bullish. The results were...分析記事 • Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...分析記事 • Jun 09
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...収支内訳
収支内訳
Innate Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 25 | 9 | -49 | 19 | 0 |
| 30 Sep 25 | 11 | -48 | 20 | 0 |
| 30 Jun 25 | 13 | -46 | 20 | 0 |
| 31 Mar 25 | 16 | -48 | 20 | 0 |
| 31 Dec 24 | 20 | -49 | 20 | 0 |
| 30 Sep 24 | 27 | -42 | 19 | 0 |
| 30 Jun 24 | 34 | -34 | 19 | 0 |
| 31 Mar 24 | 48 | -21 | 19 | 0 |
| 31 Dec 23 | 62 | -8 | 18 | 0 |
| 30 Sep 23 | 57 | -35 | 19 | 0 |
| 30 Jun 23 | 52 | -63 | 19 | 0 |
| 31 Mar 23 | 55 | -60 | 21 | 0 |
| 31 Dec 22 | 58 | -58 | 22 | 0 |
| 30 Sep 22 | 57 | -40 | 24 | 0 |
| 30 Jun 22 | 57 | -22 | 25 | 0 |
| 31 Mar 22 | 41 | -34 | 25 | 0 |
| 31 Dec 21 | 25 | -45 | 26 | 0 |
| 30 Jun 21 | 46 | -8 | 17 | 0 |
| 31 Mar 21 | 58 | -4 | 18 | 0 |
| 31 Dec 20 | 70 | -1 | 19 | 0 |
| 30 Sep 20 | 67 | -54 | 31 | 0 |
| 30 Jun 20 | 63 | -44 | 31 | 0 |
| 31 Mar 20 | 75 | -33 | 28 | 0 |
| 31 Dec 19 | 85 | 8 | 21 | 0 |
| 30 Sep 19 | 108 | 5 | 24 | 0 |
| 30 Jun 19 | 130 | 31 | 22 | 0 |
| 31 Mar 19 | 112 | 17 | 20 | 0 |
| 31 Dec 18 | 94 | 3 | 18 | 0 |
| 30 Sep 18 | 70 | -19 | 16 | 0 |
| 30 Jun 18 | 46 | -40 | 15 | 0 |
| 31 Mar 18 | 45 | -44 | 16 | 0 |
| 31 Dec 17 | 44 | -48 | 17 | 0 |
| 30 Sep 17 | 55 | -28 | 16 | 0 |
| 30 Jun 17 | 66 | -8 | 14 | 0 |
| 31 Mar 17 | 66 | 3 | 12 | 0 |
| 31 Dec 16 | 66 | 13 | 10 | 0 |
| 30 Sep 16 | 53 | 5 | 8 | 0 |
| 30 Jun 16 | 41 | -2 | 7 | 0 |
| 31 Mar 16 | 33 | -4 | 6 | 0 |
| 31 Dec 15 | 25 | -7 | 6 | 0 |
| 30 Sep 15 | 17 | -13 | 5 | 0 |
| 30 Jun 15 | 8 | -19 | 4 | 0 |
質の高い収益: IPHは現在利益が出ていません。
利益率の向上: IPHは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: IPHは利益が出ておらず、過去 5 年間で損失は年間18.6%の割合で増加しています。
成長の加速: IPHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: IPHは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 39.9% ) と比較することは困難です。
株主資本利益率
高いROE: IPHの負債は資産を上回っているため、自己資本利益率を計算することは困難です。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 20:06 |
| 終値 | 2026/05/25 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Innate Pharma S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |